S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma
Completed · Phase 3 · Has a placebo group
Conditions studied: Multiple Myeloma, Plasma Cell Neoplasm
In brief
RATIONALE: Drugs used in chemotherapy such as dexamethasone use different ways to stop cancer cells from dividing so they stop growing or die. Lenalidomide may stop the growth of multiple myeloma by stopping blood flow to the tumor. It is not yet known whether dexamethasone is more effective with or without lenalidomide in treating multiple myeloma. PURPOSE: This randomized phase III trial is studying dexamethasone and lenalidomide to see how well they work compared to dexamethasone alone in treating patients with previously untreated stage I, stage II, or stage III multiple myeloma.
Key facts
- Study ID
- NCT00064038
- Run by
- SWOG Cancer Research Network
- People needed
- 198
- Starts
- 2004-11-01
- Expected to finish
- 2012-05-01
- Last updated by the study team
- 2015-03-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- William Beaumont Hospital - Royal Oak Campus — Royal Oak, Michigan, United States
- Utah Cancer Specialists at UCS Cancer Center — Salt Lake City, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.